Indications
Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
Composition
- Active substance
- mirikizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Omvoh
- Active substance
- mirikizumab
- ATC code
- L04AC
- Therapeutic area
- Colitis, Ulcerative
- Marketing authorisation holder
- Eli Lilly Nederland B.V.
- Status
- Authorised